JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Suehiro, K.
Right arrow Articles by Burkhoff, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suehiro, K.
Right arrow Articles by Burkhoff, D.

Vol. 298, Issue 3, 1154-1160, September 2001

Selective Renal Vasodilation and Active Renal Artery Perfusion Improve Renal Function in Dogs with Acute Heart Failure

Kotaro Suehiro, Juichiro Shimizu, Geng-Hua Yi, Anguo Gu, Jie Wang, Gad Keren and Daniel Burkhoff

The Cardiac Physiology Laboratory, Divisions of Circulatory Physiology and Cardiology, Department of Medicine, Columbia University, New York, New York

Renal failure is common in heart failure due to renovascular constriction and hypotension. We tested whether selective pharmacological renal artery vasodilation and active renal artery perfusion (ARP) could improve renal function without adverse effects on systemic blood pressure in a canine model of acute heart failure (AHF). AHF was induced by coronary microembolization in 16 adult mongrel dogs. In five dogs, selective intrarenal (IR) papaverine (1, 2, and 4 mg/min) was administered into the left renal artery. In six dogs, ARP was performed in the left renal artery to normalize mean renal arterial pressure followed by administration of IR papaverine (2 mg/min). In five dogs, ARP plus intravenous furosemide was tested. Urine output (UO) and cortical renal blood flow decreased during AHF and were restored by 2 mg/min IR papaverine (UO: baseline 4.2 ± 0.6, AHF 1.6 ± 1.3, IR papaverine 5.8 ± 1.1 ml/15 min; cortical blood flow: baseline 4.3 ± 0.2, AHF 2.4 ± 0.6, IR papaverine 4.2 ± 1.2 ml/min/g) with no significant change in aortic pressure. ARP also increased urine output and cortical renal blood flow (UO: baseline 5.0 ± 1.1, AHF 0.5 ± 0.4, ARP 3.8 ± 3.1 ml/15 min; cortical blood flow: baseline 4.0 ± 0.5, AHF 2.0 ± 0.8, ARP 3.52 ± 1.1 ml/min/g). A combination of these methods in AHF further increased urine output to twice the normal baseline (10.5 ± 7.5 ml/15 min). Addition of furosemide synergistically increased UO above that achieved with ARP alone (5.5 ± 2.6 versus 40.3 ± 24.7 ml/15 min, p = 0.03). In conclusion, ARP and selective renal vasodilation may effectively promote salt and water excretion in the setting of heart failure, particularly when systemic blood pressure is low.


0022-3565/01/2983-1154$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
CirculationHome page
D. Mancini and D. Burkhoff
Mechanical Device-Based Methods of Managing and Treating Heart Failure
Circulation, July 19, 2005; 112(3): 438 - 448.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.